The latest announcement is out from PureTech Health ( (GB:PRTC) ).
PureTech Health announced its total voting rights and share capital as of February 28, 2025, with 257,927,489 issued shares and 240,189,449 voting rights. This disclosure is crucial for shareholders to determine their reporting obligations under the FCA’s rules, impacting stakeholder transparency and engagement.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to treat devastating diseases. The company has a robust pipeline of 29 therapeutics and candidates, with three FDA-approved therapies, developed through its R&D team and network of experts.
YTD Price Performance: -3.99%
Average Trading Volume: 608,413
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £345.2M
For an in-depth examination of PRTC stock, go to TipRanks’ Stock Analysis page.